

Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-100©) in liver magnetic resonance imaging in patients with known liver metastases: a phase II trial

Submission date 23/04/2007	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 01/06/2007	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 19/10/2021	Condition category Cancer	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Lars Vedin

Contact details

Floragatan 13
Stockholm
Sweden
SE-114 75
+46 (0)8 5064 5751
lv@cmc-contrast.se

Additional identifiers

Protocol serial number

CMC-P002

Study information

Scientific Title

Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-100©) in liver magnetic resonance imaging in patients with known liver metastases: a phase II trial

Study objectives

To assess the feasibility of manganese chloride tetrahydrate (CMC-001©) as a contrast medium in liver Magnetic Resonance Imaging (MRI) scanning.

The secondary objectives are to further evaluate the safety and tolerability of CMC-001© in patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the official board of the UMC St Radboud of Nijmegen on the 25th May 2004 (ref: SE/AMO 0339).

Study design

The study was open and non-randomised, with each patient being his own control. The evaluation of the MR images was performed by two independent observers.

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Verified liver metastases

Interventions

CMC-100© is a contrast agent taken by the oral route intended for use in MRI scanning of the liver, gallbladder and surrounding tissues. In this, the first phase II trial, the intention was to find out how well liver metastases could be visualised in contrast to the surrounding healthy liver tissue. To this end a MRI image taken before contrast was compared to a MRI picture taken three hours after contrast by two independent observers. Some of the patients also had a third MRI 24 hours after contrast in order to see if the gallbladder could be visualised. 48 hours after contrast the patients were called on the phone out of safety reasons in order to find out if they had experienced any Adverse Events (AEs).

No interventions besides the MRI and a screen of blood samples for safety analyses and a special blood sample for manganese analysis were done.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Manganese chloride tetrahydrate (CMC-001©) contrasting agent

Primary outcome(s)

The primary endpoint was efficacy. The MR image before contrast was compared to the MR image three hours after contrast and in a small number of patients also a MR image 24 hours after contrast.

Key secondary outcome(s)

Secondary parameters was the safety of the contrast. AEs were recorded as long as the patients were staying at the clinic and were called 48 hours after contrast and interviewed about any untoward experiences.

Completion date

01/03/2006

Eligibility**Key inclusion criteria**

1. Signed written informed consent after oral and written information about the study has been given by the investigator
2. Patients with liver metastases verified with other imaging techniques
3. Men or women over 18 years old
4. The patient is conscious and co-operative

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Clinically relevant medical history or abnormal physical findings which could interfere with the safety or objectives of the study as judged by the investigator
2. Clinically relevant haematology, clinical chemistry, serology and urine chemistry abnormalities. This is based on the judgement of the treatment physicians
3. Use of any prescribed, over-the-counter or herbal medication one week prior to entering the study, which might interfere with the safety or the objectives of this study
4. Use of all types of products containing manganese, vitamin D or products containing amino acids during the examination day until after the 24-hour examination
5. Allergy to any of the study product compounds
6. Drug or alcohol abuse by asking the patient at screening
7. Patients who are deemed to be unsuitable for any other reason in the opinion of the

investigator

8. Participation in another clinical study concerning another contrast preparation within the last three months or seven days after this study

9. Previous inclusion in this study

10. Pregnancy

11. The patient is scheduled to receive iodinated contrast medium intravascular within three days after this study

12. The patient is being investigated on an emergency basis

13. The patient has newly discovered unstable diabetes or undergoes haemodialysis or peritoneal dialysis

14. The patient has a concurrent illness that may influence the renal function or has undergone kidney transplantation

15. The patient has a concurrent illness in the Gastrointestinal (GI) tract or clinically manifest icterus

16. Known Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)

17. Hepatitis

18. The patient has uncompensated cardiac failure (cardiac failure New York Heart Association [NYHA] grade four)

19. A patient may be excluded during the trial based on the clinical judgement of the clinician or the radiologist

Date of first enrolment

01/05/2004

Date of final enrolment

01/03/2006

Locations

Countries of recruitment

Netherlands

Sweden

Study participating centre

Floragatan 13

Stockholm

Sweden

SE-114 75

Sponsor information

Organisation

Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

ROR

<https://ror.org/015x46y72>

Funder(s)

Funder type

Industry

Funder Name

Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration